A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins
Neuropsychiatric Disease and Treatment · 2011-12 · 13
DOI: 10.2147/ndt.s16085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychiatric Disease and Treatment, 2011-12. Verfasst von Joohi Jimenez-Shahed. Beteiligte Einrichtung: Department of Neurology, Baylor College of Medicine, Houston, TX, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
Zitieren
APA
Jimenez-Shahed, J. (2011). A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins. Neuropsychiatric Disease and Treatment, 13. https://doi.org/10.2147/ndt.s16085
Vancouver
Jimenez-Shahed J. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins. Neuropsychiatric Disease and Treatment. 2011:13. doi:10.2147/ndt.s16085
BibTeX
@article{JimenezShahed2011,
author = {Jimenez-Shahed, Joohi},
title = {A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins},
journal = {Neuropsychiatric Disease and Treatment},
year = {2011},
pages = {13},
doi = {10.2147/ndt.s16085}
}
EUVIMED